Ovid Therapeutics Inc. (OVID): Price and Financial Metrics


Ovid Therapeutics Inc. (OVID): $2.16

0.04 (+1.89%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add OVID to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

OVID POWR Grades


  • Value is the dimension where OVID ranks best; there it ranks ahead of 99.27% of US stocks.
  • OVID's strongest trending metric is Stability; it's been moving up over the last 179 days.
  • OVID ranks lowest in Growth; there it ranks in the 1st percentile.

OVID Stock Summary

  • OVID's current price/earnings ratio is 1.91, which is higher than only 0.81% of US stocks with positive earnings.
  • For OVID, its debt to operating expenses ratio is greater than that reported by merely 0.5% of US equities we're observing.
  • As for revenue growth, note that OVID's revenue has grown 1,551.57% over the past 12 months; that beats the revenue growth of 99.31% of US companies in our set.
  • Stocks that are quantitatively similar to OVID, based on their financial statements, market capitalization, and price volatility, are ARDX, SMCI, GPL, CLVS, and APM.
  • OVID's SEC filings can be seen here. And to visit Ovid Therapeutics Inc's official web site, go to www.ovidrx.com.

OVID Valuation Summary

  • OVID's EV/EBIT ratio is 0.2; this is 99.32% lower than that of the median Healthcare stock.
  • OVID's price/sales ratio has moved NA NA over the prior 53 months.
  • Over the past 53 months, OVID's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for OVID.

Stock Date P/S P/B P/E EV/EBIT
OVID 2021-08-31 1.1 1.2 2.0 0.2
OVID 2021-08-30 1.1 1.2 2.0 0.2
OVID 2021-08-27 1.1 1.2 2.0 0.2
OVID 2021-08-26 1.1 1.1 1.9 0.2
OVID 2021-08-25 1.1 1.2 2.0 0.3
OVID 2021-08-24 1.1 1.2 2.0 0.3

OVID's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • OVID has a Quality Grade of C, ranking ahead of 59.21% of graded US stocks.
  • OVID's asset turnover comes in at 1.419 -- ranking 13th of 682 Pharmaceutical Products stocks.
  • QURE, ACER, and SCYX are the stocks whose asset turnover ratios are most correlated with OVID.

The table below shows OVID's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 1.419 1 -10.143
2021-03-31 1.963 1 -8.584
2020-12-31 0.184 1 18.535
2020-09-30 0.099 1 -10.445
2020-06-30 0.000 NA -8.770
2020-03-31 0.000 NA -6.119

OVID Price Target

For more insight on analysts targets of OVID, see our OVID price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $4.75 Average Broker Recommendation 1.5 (Moderate Buy)

OVID Stock Price Chart Interactive Chart >

Price chart for OVID

OVID Price/Volume Stats

Current price $2.16 52-week high $4.80
Prev. close $2.12 52-week low $2.08
Day low $2.14 Volume 182,950
Day high $2.18 Avg. volume 174,168
50-day MA $3.03 Dividend yield N/A
200-day MA $3.29 Market Cap 152.10M

Ovid Therapeutics Inc. (OVID) Company Bio


Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company was founded in 2014 and is based in New York City, New York.


OVID Latest News Stream


Event/Time News Detail
Loading, please wait...

OVID Latest Social Stream


Loading social stream, please wait...

View Full OVID Social Stream

Latest OVID News From Around the Web

Below are the latest news stories about Ovid Therapeutics Inc that investors may wish to consider to help them evaluate OVID as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Good morning, trader!

William White on InvestorPlace | January 27, 2022

Is Ovid Therapeutics Inc.'s (NASDAQ:OVID) Latest Stock Performance Being Led By Its Strong Fundamentals?

Ovid Therapeutics' (NASDAQ:OVID) stock is up by 4.7% over the past month. Since the market usually pay for a company’s...

Yahoo | January 4, 2022

Ladenburg Thalmann & Co. Maintains a Buy Rating on Ovid Therapeutics (OVID)

In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Buy rating on Ovid Therapeutics (OVID – Research Report), with a price target of $7.00. The company's shares closed last Monday at $3.32. According to TipRanks.com, Higgins is a 4-star analyst with an average return of 6.2% and a 32.7% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Armata Pharmaceuticals, and Rhythm Pharmaceuticals. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Ovid Therapeutics with a $7.00 average price target.

Christine Brown on TipRanks | January 3, 2022

Ovid Therapeutics Expands Its Anti-Epileptic Franchise With AstraZeneca Licensing Pact

Ovid Therapeutics Inc (NASDAQ: OVID) has entered into an exclusive license agreement with AstraZeneca plc (NASDAQ: AZN) for a library of early-stage small molecules targeting the KCC2 transporter, including a lead candidate, OV350. The Company seeks to optimize and accelerate the development of these KCC2 transporter activators in epilepsies and potentially other neuropathic conditions. Under the agreement terms, AstraZeneca will receive an upfront payment of $5 million in cash and $7.5 million

Yahoo | January 3, 2022

Ovid Therapeutics Expands Epilepsy Franchise with Novel KCC2 Activators

Exclusive license from AstraZeneca adds a unique candidate and a broad library of compounds to Ovid’s franchise of potential first-in-class anti-epileptic therapiesCollaboration with Dr. Stephen Moss, founder of Tufts Laboratory for Basic and Translational Neuroscience Research, and expert team in neuropharmacologyTransaction is the first business development activity that seeks to enhance Ovid’s pipeline of small-molecule and genetic CNS medicines NEW YORK, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Ovi

Yahoo | January 3, 2022

Read More 'OVID' Stories Here

OVID Price Returns

1-mo N/A
3-mo -32.50%
6-mo -35.91%
1-year -41.14%
3-year 146.86%
5-year -71.10%
YTD -32.71%
2021 38.96%
2020 11.33%
2019 71.49%
2018 -75.48%
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7572 seconds.